Devyser launches the first IVDR compliant NGS assay for thalassemia and sickle cell disease testing
Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing...
Oncology | September 7, 2022
With cancer identified as the leading cause of death in high-income countries, early identification and treatment of cancer, and potential cancer-causing genetic variants, is essential. As the second most common cancer worldwide, and the most frequently diagnosed cancer among women, breast cancer nonetheless has a high survival rate if diagnosed and treated.
Read more about the simple identification of both BRCA1 and BRCA2 genes in the whitepaper:
Next Generation Sequencing – Full gene sequencing of BRCA1 and BRCA2
Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing...
Read More
Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announces that it has...
Read More
Devyser today announced that it entered a strategic agreement with Illumina, a global leader in DNA...
Read More
Devyser is proud to announce that the company has been awarded a tender by Oslo University Hospital...
Read More